I agree that CTSO will continue to move up, how much is anyone's guess. At a pps of $10 the market cap will be around $300MM. When the cardiac partner is announce it will be interesting to hear what they may say regarding market size and potential - US and world. That should provide an impenitence for further price appreciation. I expect that to be in the range of $500MM to $1,500MM and I would expect the market cap to approach $500MM - a PPS of $18.
EAP designation would infer that the filter is a viable medical device with huge potential. I think the market cap could then double from there. If the momentum traders get involved with this stock of only 30MM shares who knows what might happen with the pps.
If it was that important you could research the company and see if they have a website with an email address or a phone number. Once you completed your research you could contact them. That way you won't frustrate yourself posting questions on a message board and not getting the answers you rightly so deserve.
Call Cytosorbents and get them to answer your questions - then comeback to the message board and share them.
If it such a concern why don't you ask that of Amy Vogel? Perhaps she can give you the broader feedback that would allay your anxiety.
Roberts is getting serious, who knows were the price of oil is going but hopefully it will stabilize. I would like to see the loonie get stronger. From the press release:
we will limit our capital expenditures to funds flow from operations by year-end 2015
we will suspend our dividend and reduce board compensation
we will significantly reduce our cost structure through a 35% workforce reduction
"We continue to take concrete steps to strengthen our balance sheet," said Dave Roberts, President and CEO of Penn West, "Limiting our capital programs to the funds flow generated from our assets and suspending our dividend are necessary steps. Building on a combination of process and efficiency improvements over the past 12 to 18 months, we are taking further actions today to significantly reduce our cost structure without impacting our ability to execute. We remain flexible and well positioned to move forward when oil prices improve."
I am not knowledgeable about how trading desks works, but I put in a small limit order and it was filled 100 shares at a time, it just took a while to complete.
Within the next two weeks we should get some statements regarding the future direction/status of Cart T cell Partnership,EAP and Cardiac Partner. Hopefully we will learn more about Fresenius sales projections. We shave a lot to look forwards too.
ping - I can see why you would say that, but we all know the second quarter is going to be more like the first quarter. Going forward Dr. Chan said during the second half CTSO sales would be back on track.
My interpretation on the shelf offering is that the "potential" cardiac partner, for whatever reason, decided not to pony up as much cash ( or agree to terms) as what CTSO may have wanted, leaving the company to file the shelf offering to finance future trials.
As for the future, I think the arrangement with Fresenius will be a catalyst for CTSO.
What are your expectations that have tempered your future outlook?
As always, thanks for your input.
A $40 pps would mean a little more than a billion $ market cap. We could get that on some positive news. Without having to wait for sales.
mr_p, thanks for your garnishing and sharing of facts. While inclusion of CTSO into the Russell micro-cap gives the company credibility as a viable corporate entity, it doesn't look like inclusion by itself will not do much for demand of the stock to to move the pps.
While the dollar amount is nominal, the fact that the doctor recognized using the filter as a viable therapy is extremely significant!